As the global drone, AI infrastructure, and autonomous systems markets accelerate, the industry's next major challenge is shifting from keeping drones in the air to keeping them securely connected. While manufacturers continue improving flight time, payload capacity, and onboard AI, the real bottleneck is increasingly becoming wireless signal communications —the ability to move massive amounts of mission-critical data securely, reliably, and in real time across increasingly crowded and contested environments.
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 95.7% to $1.4 during Wednesday's regular session. The market value of their outstanding shares is at $2.5 million. Tvardi Therapeutics (NASDAQ:TVRD)
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 55.8% to $1.11 during Wednesday's pre-market session. The company's market cap stands at $2.5 million. Innovative Eyewear (NASDAQ:LUCY) shares
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 34.7% to $0.96 during Tuesday's after-market session. The company's market cap stands at $2.0 million. Ironwood Pharmaceuticals (NASDAQ:IRWD)
While much of Wall Street's attention remains focused on artificial intelligence giants and multi-billion-dollar semiconductor companies, Peraso Inc. (NASDAQ: PRSO) continues to quietly build a position in several of the fastest-growing technology markets, including military drones, AI infrastructure, autonomous systems, secure communications, robotics, and electronic warfare .
Gainers Pulsenmore (NASDAQ:PLSM) stock increased by 152.0% to $8.59 during Wednesday's pre-market session. The company's market cap stands at $22.1 million. Catheter Precision (AMEX:VTAK) shares rose 44.56% to
IGC Pharma, Inc. (NYSE: IGC) a clinical-stage Biotechnology company developing treatments for Alzheimer's Disease and Artificial Intelligence (AI) enabled healthcare technologies, today announced the beta release of its proprietary Agentic Harmonization Assistant ("AHA"), a patent-pending Healthcare AI platform designed to accelerate Alzheimer's Drug Discovery, Clinical Research , Precision Medicine , and Pharmaceutical Development by helping researchers quickly combine and organize Alzheimer's disease , aging-related, and other medical data that is often scattered across multiple databases, studies, hospitals, clinical trials, healthcare systems, and research institutions.
